Noticias y eventos de Sanofi SA (SNY)SNYSanofi SA

ScionxBio Enters Global Strategic Collaboration with Sanofi

ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio's proprietary TERA platform. This agreement brings together the global expertise of Sanofi's mRNA Center of Excellence, with ScionxBio's TERA platform. This collaboration represents a critical step in expanding the xRNA modality into a new direction, utilizing the technology for novel, long-acting applications across a multitude of potential indications. Powered by advanced deep learning architectures, the platform deciphers the complex structure-activity relationships within high-throughput combinatorial screens to engineer next-generation molecules. These molecules feature uniquely designed and chemically synthesized regulatory elements that provide greater stability and resistance to enzymatic degradation compared to traditional mRNA, facilitating the sustained, high-level protein expression necessary for therapeutic success in vivo. While undisclosed, the disease areas covered by the collaboration address conditions where sustained protein expression is essential for robust and competitive clinical effects. The enhanced stability and expression profile of the platform aligns perfectly with the goal of developing life-changing, durable medicines for challenging indications. ScionxBio will lead optimization activities up to in vivo validation stages. Sanofi will then assume responsibility for all remaining preclinical development activities, Investigational New Drug-enabling studies, clinical development, manufacturing, and worldwide commercialization. The proprietary technology represents a significant advancement in the mRNA therapeutics field, providing a robust and durable solution for both inherited and acquired protein deficiencies. By utilizing an extensive toolbox of well-validated chemical modifications, the technology is poised to transform the treatment landscape for chronic conditions. Beyond simple protein replacement, the TERA platform is envisioned to produce extended exposure to cardiometabolic or immune corrective modulators, thus potentially serving as a new class of disease-modifying and preventive agents.

Dow Rises 556.21 Points, Nasdaq Ends Little Changed

The Dow advanced and the Nasdaq finished little changed, but ended well off its worst levels, as concerns around overspending on AI led to underperformance in the tech-heavy index. Meanwhile, the producer price index rose 1.3% month over month, the largest increase since March 2022, following a 0.4% gain in August and exceeding economists' expectations for a 0.6% advance. On an annual basis, producer prices climbed 6.3%, up from 5.6% in August and the highest rate since December 2022.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Anthropic informed prospective investors that its Q3 revenue reached $16.8B, as the Claude maker forges ahead with plans for an IPO, Bloomberg reportsTSMCreported better-than-expected Q3 resultsPenske Automotiveagreed to be taken private in a $16.3B transactionCCC Intelligent Solutionsagreed to be acquired by GTCR and Elliott for $6.1BMetarolled out Muse Spark Open on AppleM5 Ultra Macs2. WALL STREET CALLS:Deutsche Bank upgraded Walmartto Buy on favorable 2027 setupSpotifydowngraded to Hold at StoneX on "tempered" gross margin viewQuantinuumupgraded to Overweight at Morgan StanleyPayPalreinstated at Underperform, down from Neutral, at BofACarMaxdouble upgraded to Buy from Underperform at BofA3. AROUND THE WEB:Appleclosed above a $5T market capitalization on Wednesday, ending the day at $5.005T, the second company after Nvidiato do so, WSJ reportsLone Star and Atlas Holdings are both exploring "multibillion-dollar bids" for International Paper'sEuropean packaging business, previously known as DS Smith, FT saysNvidia CEO Jensen Huang said the chipmaker "absolutely must" work with Chinese AI companies on monitoring risks, telling CNBC that AI is "potentially dangerous," and that he has ongoing "dialogues" with researchers in ChinaSpaceXhas restricted some Starlink services in Ukraine by disabling military-grade terminals traveling above 100 mph, Reuters reportsSignet Jewelersand Richemontare in talks to join the Global Diamond Consortium to buy diamond miner De Beers from Anglo American, Bloomberg says4. MOVERS:OPKO Healthgained after entering into an agreement for Labcorpto acquire select assets of OPKO Health subsidiary BioReference HealthEricssonincreased in New York after reporting Q3 results and announcing with Verizonthe completion of the first 6G field callRecursion Pharmaceuticalswas higher after reporting data from its REC-1245 and REC-4881 trials, announcing Sanofioptioned the first development candidate from their multi-program research collaboration, and pricing 61.54M shares of its stockCybersecurity companies including CrowdStrikeand Palo Alto Networkswere lower after Semafor reported that Perplexity is "giving away" its AI sandbox SPACEAquestive Therapeuticsfell after announcing the FDA acknowledged its resubmission of the NDA for Anaphylm sublingual film5. EARNINGS/GUIDANCE:FMCcut its Q3 revenue guidance, saying it is facing slower-than-expected demand from channel customers in key marketsPrologisreported Q3 results and raised its outlook for FY26, with CEO Daniel Letter saying the company "executed well" this quarter"ManpowerGroupreported Q3 results, with EPS in-line with consensusU.S. Bancorpreported Q3 results, provided guidance for Q4, and raised its outlook for FY26PNC Financialreported Q3 results with EPS beating consensusINDEXES:The Dow rose 556.21, or 1.08%, to 52,177.69, the Nasdaq gained 20.16, or 0.08%, to 26,713.03, and the S&P 500 advanced 25.12, or 0.33%, to 7,744.06.

Sanofi Completes Agreement with Pan-Canadian Pharmaceutical Alliance

Sanofi announced the successful completion of negotiations between the pan-Canadian Pharmaceutical Alliance and Sanofi with a signed Letter of Intent for Dupixent for four additional indications: atopic dermatitis in pediatric patients, prurigo nodularis, severe chronic rhinosinusitis with nasal polyposis, and chronic obstructive pulmonary disease. Sanofi said it looks forward to working with public payers to support access for eligible patients. "This agreement with the pCPA is an important step forward in expanding patient access to the first advanced biologic therapy approved for pediatric atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and COPD," said James Guy, General Manager, Specialty Care and Country Lead, Sanofi Canada.